يعرض 1 - 10 نتائج من 928 نتيجة بحث عن '"Dane, Faysal"', وقت الاستعلام: 1.02s تنقيح النتائج
  1. 1
  2. 2
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    المساهمون: DEMİRCAN N. C. , ENGÜR C. Ö. , AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., Yasar A., Celebi A., Alan O., Isik S., ÖZGÜVEN S.

    وصف الملف: application/pdf

    العلاقة: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY; DEMİRCAN N. C. , ENGÜR C. Ö. , AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., Yasar A., Celebi A., Alan O., Isik S., ÖZGÜVEN S., et al., "Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib", TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2022; https://avesis.marmara.edu.tr/api/publication/2482eef0-b7ee-4316-ab4f-f59b5426bbbe/fileTest; https://hdl.handle.net/11424/282223Test

  6. 6
    دورية أكاديمية

    المؤلفون: DANE, FAYSAL

    المساهمون: YASİN A. İ., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli C., Ozturk A., Perkin P., Demirtas D., Erdemoglu E.

    وصف الملف: application/pdf

    العلاقة: FUTURE ONCOLOGY; YASİN A. İ., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli C., Ozturk A., Perkin P., Demirtas D., Erdemoglu E., et al., "Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study", FUTURE ONCOLOGY, cilt.18, ss.1235-1244, 2022; 1244; 1235; https://hdl.handle.net/11424/286170Test; 18

  7. 7
    دورية أكاديمية

    المساهمون: AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., Yasar A., Majidova N., Celebi A., EROL B.

    وصف الملف: application/pdf

    العلاقة: Nutrition and Cancer; AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., Yasar A., Majidova N., Celebi A., EROL B., et al., "Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma", Nutrition and Cancer, cilt.74, sa.7, ss.2499-2507, 2022; 2507; 2499; https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85129222123&origin=inwardTest; https://hdl.handle.net/11424/289036Test; 74

  8. 8
    دورية أكاديمية

    المؤلفون: DANE, FAYSAL

    المساهمون: Isikdogan A., Turk H., Bilir C., Sendur M., Karabulut B., Artac M., Cicin I., Geredeli C., Alacacioglu A., Kefeli U.

    وصف الملف: application/pdf

    العلاقة: ANNALS OF ONCOLOGY; Isikdogan A., Turk H., Bilir C., Sendur M., Karabulut B., Artac M., Cicin I., Geredeli C., Alacacioglu A., Kefeli U., et al., "First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis", ANNALS OF ONCOLOGY, cilt.33, 2022; https://avesis.marmara.edu.tr/api/publication/3e87dfd9-3708-43ac-a1b8-ef20721245c7/fileTest; https://hdl.handle.net/11424/282107Test; 33

  9. 9
    دورية أكاديمية

    المؤلفون: DANE, FAYSAL

    المساهمون: Artac M., Cubukcu E., Bozkurt O., Bilici A., Celik S., Ozcelik M., Oven B., Simsek E., Geredeli C., Karaca M.

    وصف الملف: application/pdf

    العلاقة: ANNALS OF ONCOLOGY; Artac M., Cubukcu E., Bozkurt O., Bilici A., Celik S., Ozcelik M., Oven B., Simsek E., Geredeli C., Karaca M., et al., "Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study", ANNALS OF ONCOLOGY, cilt.33, 2022; https://avesis.marmara.edu.tr/api/publication/209bfd47-a068-4c47-a9b4-a033565c9df4/fileTest; https://hdl.handle.net/11424/282076Test; 33

  10. 10
    دورية أكاديمية

    المساهمون: AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T.

    وصف الملف: application/pdf

    العلاقة: ANNALS OF NUCLEAR MEDICINE; AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T., et al., "Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment", ANNALS OF NUCLEAR MEDICINE, 2022; https://hdl.handle.net/11424/282075Test